Paper Details

  1. Home
  2. Paper Details

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

Author: ButlerA, CooperS J, RaniwallaJ, TweedJ, WelchC

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. The 26-week risk of recurrence was six times lower in the zotepine group than in the placebo group. There was no significant difference between the groups with respect to extrapyramidal side effects.
Paper Details　
Original Abstract of the Article :
RATIONALE: Zotepine is an antipsychotic drug with proven efficacy for treatment of acute episodes of schizophrenia. Antipsychotic drugs also require to be effective in prevention of recurrence. OBJECTIVE: This trial was designed to compare the effects of zotepine and placebo in the prevention of re...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s002130000452

データ提供：米国国立医学図書館（NLM）

Zotepine: A Beacon in the Desert of Schizophrenia

This study tackles the challenging landscape of chronic schizophrenia, a condition that often leads to recurrent episodes. It's like navigating a vast and sometimes treacherous desert, searching for a reliable remedy to prevent those episodes. The researchers tested the efficacy of zotepine, an antipsychotic drug, against placebo in patients with chronic schizophrenia. Their findings suggest that zotepine is a valuable tool in the fight against recurrent episodes, offering a potential oasis of stability for those struggling with this condition.

Zotepine: A Promise of Stability

The results show that zotepine significantly reduced the risk of recurrence in patients with chronic schizophrenia. This offers a ray of hope, suggesting that zotepine can provide a more stable and predictable course for individuals with this challenging condition.

Living Well in the Desert of Schizophrenia

This study offers a positive message for those living with chronic schizophrenia. It emphasizes the importance of finding the right treatment to prevent recurrent episodes and improve overall well-being. While it's not a guaranteed cure, zotepine might be a valuable ally in navigating the complexities of this condition.

Dr. Camel's Conclusion

This research presents zotepine as a promising treatment option for preventing recurrence in chronic schizophrenia. It offers a beacon of hope, signifying a potential path toward greater stability and improved quality of life for those affected by this challenging condition.
Date :
  1. Date Completed 2000-12-07
  2. Date Revised 2019-07-26
Further Info :

Pubmed ID

10923750

DOI: Digital Object Identifier

10.1007/s002130000452

Related Literature

Article Analysis
・Effective treatment of schizophrenia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.